Efficacy and Safety of Pitavastatin in Children and Adolescents at High Future Cardiovascular Risk.
To assess the safety and efficacy of pitavastatin in children and adolescents with hyperlipidemia. A total of 106 children and adolescents with hyperlipidemia, ages 6 to 17 years, were enrolled in a 12-week randomized, double-blind, placebo-controlled study and randomly assigned to pitavastatin 1 mg, 2 mg, 4 mg, or placebo. During a 52-week extension period, subjects were up-titrated from 1 mg pitavastatin to a maximum dose of 4 mg in an effort to achieve an optimum low-density lipoprotein cholesterol (LDL-C) treatment target of <110 mg/dL (2.8 mmol/L). Adverse events rates, including abnormal clinical laboratory variables, vital signs, and physical examination were assessed. Compared with placebo, pitavastatin 1, 2, and 4 mg significantly reduced LDL-C from baseline by 23.5%, 30.1%, and 39.3%, respectively, and in the open-label study 20.5% of the subjects reached the LDL-C goal <110 mg/dL (2.8 mmol/L). No safety issues were evident. Pitavastatin at doses up to 4 mg is well tolerated and efficacious in children and adolescents aged 6-17 years. Registered with EudraCT 2011-004964-32 and EudraCT 2011-004983-32.